Pulmonary Medcine, Northwestern University, Chicago, IL.
Pulmonary Medcine, University of Washington, Seattle, WA.
Chest. 2021 Nov;160(5):e399-e408. doi: 10.1016/j.chest.2021.05.075. Epub 2021 Jul 30.
The existing coverage criteria for noninvasive ventilation (NIV) do not recognize the benefits of early initiation of NIV for those with thoracic restrictive disorders and do not address the unique needs for daytime support as the patients progress to ventilator dependence. This document summarizes the work of the thoracic restrictive disorder Technical Expert Panel working group. The most pressing current coverage barriers identified were: (1) delays in implementing NIV treatment; (2) lack of coverage for many nonprogressive neuromuscular diseases; and (3) lack of clear policy indications for home mechanical ventilation (HMV) support in thoracic restrictive disorders. To best address these issues, we make the following key recommendations: (1) given the need to encourage early initiation of NIV with bilevel positive airway pressure devices, we recommend that symptoms be considered as a reason to initiate therapy even at mildly reduced FVCs; (2) broaden CO measurements to include surrogates such as transcutaneous, end-tidal, or venous blood gas; (3) expand the diagnostic category to include phrenic nerve injuries and disorders of central drive; (4) allow a bilevel positive airway pressure device to be advanced to an HMV when the vital capacity is < 30% or to address severe daytime respiratory symptoms; and (5) provide additional HMV when the patient is ventilator dependent with use > 18 h per day. Adoption of these proposed recommendations would result in the right device, at the right time, for the right type of patients with thoracic restrictive disorders.
现有的无创通气(NIV)覆盖标准没有认识到早期开始 NIV 对患有胸壁限制性疾病患者的益处,也没有解决随着患者进展为呼吸机依赖,白天需要支持的独特需求。本文总结了胸壁限制性疾病技术专家小组工作组的工作。目前最紧迫的覆盖障碍包括:(1)延迟实施 NIV 治疗;(2)许多非进行性神经肌肉疾病未得到覆盖;(3)胸壁限制性疾病的家庭机械通气(HMV)支持缺乏明确的政策指示。为了最好地解决这些问题,我们提出以下关键建议:(1)鉴于需要鼓励早期使用双水平气道正压通气设备开始 NIV,我们建议即使在 FVC 轻度降低的情况下,也可以将症状视为开始治疗的原因;(2)拓宽 CO 测量范围,包括经皮、呼气末或静脉血气等替代指标;(3)扩大诊断类别,包括膈神经损伤和中枢驱动障碍;(4)当肺活量<30%或严重白天呼吸症状时,允许将双水平气道正压通气设备升级为 HMV;(5)当患者每天使用呼吸机依赖超过 18 小时时,提供额外的 HMV。采用这些建议将导致为患有胸壁限制性疾病的正确类型的患者在正确的时间提供正确的设备。